After Wolfspeed (NYSE: WOLF) stock plummeted 84.7% in 2024, investors had high hopes that shares would rebound in 2025 and ride the bullish wave that had recently driven so many semiconductor ...

Jazz Pharma has bolstered its pipeline of cancer drugs through a $1.3 billion licensing agreement with Werewolf Therapeutics that adds its first immuno-oncology candidate. The Dublin-based pharma ...